The U.S. small molecule drug discovery outsourcing market size was estimated at USD 1.52 billion in 2024 and is projected to reach USD 3.47 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. Increasing R&D expenses, rising focus on early-stage research activities, and growing biotech companies with limited in-house resources drive the market.
Besides, outsourcing has emerged as a strategic option for pharmaceutical and biotech companies aiming to accelerate the timelines, lower fixed overhead costs, and gain access to specialized expertise in areas such as medicinal chemistry, hit-to-lead optimization, ADME/PK studies, and IND-enabling activities.
Innovations like AI-driven compound design, CRISPR-based target validation, high-throughput screening, and 3D cell models transform discovery processes, enabling contract research organizations (CROs) to provide more efficient and predictive results. Furthermore, rising R&D costs, increased demand for drug development, and a shift towards virtual pharmaceutical models support the market. In addition, an increase in registered clinical studies, a higher approval rate for small molecule drugs, advancements in medical technology, a rise in diseases being studied, and the urgent need for new treatments are anticipated to drive the market.
This product will be delivered within 1-3 business days.
Besides, outsourcing has emerged as a strategic option for pharmaceutical and biotech companies aiming to accelerate the timelines, lower fixed overhead costs, and gain access to specialized expertise in areas such as medicinal chemistry, hit-to-lead optimization, ADME/PK studies, and IND-enabling activities.
Innovations like AI-driven compound design, CRISPR-based target validation, high-throughput screening, and 3D cell models transform discovery processes, enabling contract research organizations (CROs) to provide more efficient and predictive results. Furthermore, rising R&D costs, increased demand for drug development, and a shift towards virtual pharmaceutical models support the market. In addition, an increase in registered clinical studies, a higher approval rate for small molecule drugs, advancements in medical technology, a rise in diseases being studied, and the urgent need for new treatments are anticipated to drive the market.
U.S. Small Molecule Drug Discovery Outsourcing Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. small molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, and end use:Workflow Outlook (Revenue, USD Million, 2021 - 2033)
- Target Identification & Screening
- Target Validation & Functional Informatics
- Lead Identification & Candidate Optimization
- Preclinical Development
- Others
Service Outlook (Revenue, USD Million, 2021 - 2033)
- Chemistry Services
- Biology Services
Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
- Respiratory system
- Pain and Anesthesia
- Oncology
- Ophthalmology
- Hematology
- Cardiovascular
- Endocrine
- Gastrointestinal
- Immunomodulation
- Anti-infective
- Central Nervous System
- Dermatology
- Genitourinary System
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical & Biotechnology companies
- Academic Institutes
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Research Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Small Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope
Chapter 4. U.S. Small Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis
Chapter 5. U.S. Small Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis
Chapter 6. U.S. Small Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis
Chapter 7. U.S. Small Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Charles River Laboratories
- Laboratory Corporation of America Holdings (Covance)
- Albany Molecular Research (Curia)
- Merck & Co., Inc.
- QIAGEN
- Eurofins
- Evotec
- GenScript Biotech
- Pharmaron
- Syngene International
- Dalton Pharma Services
- Oncodesign
- Jubilant Biosys
- Domainex
- Dr. Reddy Laboratories Ltd.
- Pharmaron Beijing Co., Ltd.
- TCG Lifesciences Pvt Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 120 |
Published | July 2025 |
Forecast Period | 2024 - 2033 |
Estimated Market Value ( USD | $ 1.52 Billion |
Forecasted Market Value ( USD | $ 3.47 Billion |
Compound Annual Growth Rate | 9.7% |
Regions Covered | United States |
No. of Companies Mentioned | 17 |